Treatment-resistant medication overuse headache can be cured

Headache

Volumn 52, Issue 7, 2012, Pages 1120-1129

  Munksgaard, Signe B ^a   Bendtsen, Lars ^a   Jensen, Rigmor H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

follow up; medication overuse headache; multidisciplinary treatment; outpatient treatment; treatment resistant headache

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; FLUNARIZINE; LEVOMEPROMAZINE; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROMETHAZINE; TOPIRAMATE; TRIPTAN DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TERTIARY HEALTH CARE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANALGESICS; DELIVERY OF HEALTH CARE, INTEGRATED; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HEADACHE DISORDERS, SECONDARY; HUMANS; INCIDENCE; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; NURSES; PHYSICAL THERAPISTS; PHYSICIANS; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863728678     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2012.02191.x     Document Type: Article

References (33)

1. Stovner LJ, Andree C,. Prevalence of headache in Europe: A review for the Eurolight project. J Headache Pain. 2010; 11: 289-299.
2. Evers S, Marziniak M,. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol. 2010; 9: 391-401.
3. Linde M, Gustavsson A, Stovner LJ, et al,. The cost of headache disorders in Europe: The Eurolight project. Eur J Neurol. 2012; 19: 703-711.
4. Haag G, Baar H, Grotemeyer KH, Pfaffenrath V, Ribbat MJ, Diener HC,. Prophylaxe und Therapie des medikamenteninduzierten Dauerkopfschmerzes. Schmerz. 1999; 13: 52-57.
5. Grande RB, Aaseth K, Benth JS, Lundqvist C, Russell MB,. Reduction in medication-overuse headache after short information. The Akershus study of chronic headache. Eur J Neurol. 2011; 18: 129-137.
6. Rossi P, Faroni JV, Nappi G,. Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. Eur J Neurol. 2010; 18: 396-401.
7. Hagen K, Jensen R, Boe MG, Stovner LJ,. Medication overuse headache: A critical review of end points in recent follow-up studies. J Headache Pain. 2010; 11: 373-377.
8. Diener HC, Silberstein SD,. Medication overuse headaches. In:, Olesen J, Goadsby PJ, Ramadan N, Tfelt-Hansen P, Welch KMA, eds. The Headaches. Philadelphia, PA: Lippincott Williams & Wilkins; 2006: 971-979.
9. Hagen K, Albretsen C, Vilming S, et al,. Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia. 2008; 29: 221-232.
10. Jensen R, Zeeberg P, Dehlendorff C, Olesen J,. Predictors of outcome of the treatment programme in a multidisciplinary headache centre. Cephalalgia. 2010; 30: 1214-1224.
11. Olesen J, Bousser MG, Diener HC, et al,. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006; 26: 742-746.
12. Russell MB, Rasmussen BK, Brennum J, Iversen HK, Jensen RA, Olesen J,. Presentation of a new instrument: The diagnostic headache diary. Cephalalgia. 1992; 12: 369-374.
13. Munksgaard SB, Bendtsen L, Jensen RH,. Detoxification of medication-overuse headache by a multidisciplinary treatment programme is highly effective: Proposals for the optimal detoxification programme. Cephalalgia. 2012 (in press).
14. Bendtsen L, Evers S, Linde M, Mitsikostas DD, Sandrini G, Schoenen J,. EFNS guideline on the treatment of tension-type headache-Report of an EFNS task force. Eur J Neurol. 2010; 17: 1318-1325.
15. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sandor PS,. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol. 2009; 16: 968-981.
16. Stewart WF, Lipton RB, Dowson AJ, Sawyer J,. Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology. 2001; 56: S20-S28.
17. Saxena S, Orley J,. Quality of life assessment: The World Health Organization perspective. Eur Psychiatry. 1997; 12S3: 263s-266s.
18. Crawford JR, Henry JD, Crombie C, Taylor EP,. Normative data for the HADS from a large non-clinical sample. Br J Clin Psychol. 2001; 40: 429-434.
19. BÃe MG, Salvesen R, Mygland A,. Chronic daily headache with medication overuse: A randomized follow-up by neurologist or PCP. Cephalalgia. 2009; 29: 855-863.
20. Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener HC, Limmroth V,. Medication overuse headache: Rates and predictors for relapse in a 4-year prospective study. Cephalalgia. 2005; 25: 12-15.
21. Sances G, Ghiotto N, Galli F, Guaschino E, Rezzani C, Guidetti V, Nappi G,. Risk factors in medication-overuse headache: A 1-year follow-up study (care II protocol). Cephalalgia. 2010; 30: 329-336.
22. Zidverc-Trajkovic J, Pekmezovic T, Jovanovic Z, Pavlovic A, Mijajlovic M, Radojicic A, Sternic N,. Medication overuse headache: Clinical features predicting treatment outcome at 1-year follow-up. Cephalalgia. 2007; 27: 1219-1225.
23. Katsarava Z, Limmroth V, Finke M, Diener HC, Fritsche G,. Rates and predictors for relapse in medication overuse headache: A 1-year prospective study. Neurology. 2003; 60: 1682-1683.
24. Andrasik F, Grazzi L, Usai S, D'Amico D, Kass S, Bussone G,. Disability in chronic migraine with medication overuse: Treatment effects at 3 years. Headache. 2007; 47: 1277-1281.
25. Rossi P, Faroni JV, Nappi G,. Medication overuse headache: Predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia. 2008; 28: 1196-1200.
26. Usai S, Grazzi L, D'Amico D, Andrasik F, Bussone G,. Psychological variables in chronic migraine with medication overuse before and after inpatient withdrawal: Results at 1-year follow-up. Neurol Sci. 2009; 30 (Suppl. 1): S125-S127.
27. Zeeberg P, Olesen J, Jensen R,. Discontinuation of medication overuse in headache patients: Recovery of therapeutic responsiveness. Cephalalgia. 2006; 26: 1192-1198.
28. Grazzi L, Andrasik F, Usai S, Bussone G,. In-patient vs. day-hospital withdrawal treatment for chronic migraine with medication overuse and disability assessment: Results at one-year follow-up. Neurol Sci. 2008; 29 (Suppl. 1): S161-S163.
29. Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V,. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology. 2001; 57: 1694-1698.
30. Mei D, Ferraro D, Zelano G, Capuano A, Vollono C, Gabriele C, Di Trapani G,. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol. 2006; 29: 269-275.
31. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ,. Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia. 2007; 27: 814-823.
32. Gunreben-Stempfle B, Griessinger N, Lang E, Muehlhans B, Sittl R, Ulrich K,. Effectiveness of an intensive multidisciplinary headache treatment program. Headache. 2009; 49: 990-1000.
33. Holroyd KA, Cottrell CK, O'Donnell FJ, Cordingley GE, Drew JB, Carlson BW, Himawan L,. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: Randomised controlled trial. BMJ. 2010; 341: c4871.